Paraneoplastic Evaluation Algorithm – Serum

The following tests are always performed:

- Antineuronal nuclear antibody-type 1 (ANNA-1)
- Antineuronal nuclear antibody-type 2 (ANNA-2)
- Antineuronal nuclear antibody-type 3 (ANNA-3)
- Purkinje cell cytoplasmic antibody, type 1 (PCA-1)
- Purkinje cell cytoplasmic antibody, type 2 (PCA-2)
- Purkinje cell cytoplasmic antibody, type Tr (PCA-Tr)
- Anti-glial/neuronal nuclear antibody-type 1 (AGNA-1)
- Amphiphysin antibody assay
- Collapsin response-mediator protein-5 neuronal (CRMP-5-IgG)

Immunofluorescence (IFA)

- ANNA-1 antibody by immunoblot
- ANNA-2 antibody by immunoblot
- ANNA-3 antibody by IF titer assay
- AGNA-1 antibody by immunoblot
- AGNA-1 antibody by IF titer assay
- PCA-1 antibody by immunoblot
- PCA-1 antibody by IF titer assay
- PCA-2 antibody by immunoblot
- PCA-2 antibody by IF titer assay
- CRMP-5-IgG

Radioimmunoprecipitation (RIA)

- P/Q-type calcium channel antibody
- Neuronal voltage-gated potassium channel (VGKC) autoantibody
- Contactin-associated protein-like-2 (CASPR2)-IgG
- Leucine-rich glioma inactivated protein-1 IgG

If neuronal VGKC autoantibody is ≥0.01 nmol/L